JAWHARI ENDOSCOPY LIMITED

Executive Summary

Jawhari Endoscopy Limited is a newly formed micro-entity in the specialist medical practice sector with solid net assets and no overdue statutory filings, indicating low short-term financial and compliance risks. However, its very recent incorporation and small operational scale present challenges in assessing long-term stability. Further due diligence on cash flow and governance is recommended to fully understand the company’s risk profile.

JAWHARI ENDOSCOPY LIMITED - Analysis Report

Company Number: 14686120

Analysis Date: 2025-07-29 15:14 UTC

1. Risk Rating: LOW
   Jawhari Endoscopy Limited demonstrates a solid net asset position with increasing net current assets and shareholders’ funds over the reported periods. The company is current on its statutory filings and is not subject to liquidation or other insolvency proceedings, indicating low immediate solvency and compliance risk.

2. Key Concerns:

• The company is very young, incorporated in early 2023, with limited financial history, making long-term operational stability harder to assess.
• The business is categorized as a micro-entity with minimal assets and a single employee, which may limit operational scale and resilience.
• There is concentration of control between two individuals who each hold significant shares and voting rights, which could present governance risks if disagreements arise.

3. Positive Indicators:

• The company maintains a comfortable net current asset position (£34,211 as of 2025) with current assets exceeding current liabilities by a healthy margin.
• Timely filing of accounts and confirmation statements with no overdue submissions reflect good regulatory compliance and governance practices.
• The director, who is also a hospital doctor, adds relevant industry expertise aligned with the company’s specialist medical practice classification (SIC 86220).

4. Due Diligence Notes:

• Review detailed financial performance and cash flow statements (not currently provided) to confirm liquidity beyond balance sheet strength.
• Verify the nature and sustainability of revenue streams, given the small scale and early stage of the company.
• Assess the impact of shareholder concentration on decision-making and potential succession or exit strategies.
• Confirm the absence of related party transactions or contingent liabilities not disclosed in the financial statements.
• Monitor ongoing compliance with filing deadlines and potential changes in operational scale or employee count.